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ABSTRACT
We compared the functional status of the hypothalamic dopaminergic tone in patients given an allogeneic
hematopoietic stem cell transplantation (allo-HSCT) with chronic graft-versus-host disease (GVHD) with that
observed in patients with allo-HSCT without chronic GVHD and in healthy controls. The effect of acute
dopaminergic blockade with intravenous metoclopramide on serum prolactin (PRL) concentrations was
evaluated. Twenty volunteers, 20 to 52 years of age, seronegative for both hepatitis C virus and the human
immunodeficiency virus, were studied: (1) 10 clinically healthy men (group 1), and (2) 9 patients with leukemia,
and 1 patient with refractory aplastic anemia who underwent allo-HSCT, 5 of whom (3 men and 2 women)
developed chronic GVHD (group 2), and 5 (3 men and 2 women) who did not develop chronic GVHD (group
3). Serum PRL concentrations were measured both fasting and after intravenous administration of metoclo-
pramide (10-mg bolus). The area under the PRL curve was calculated. Patients in group 2 were older than
those in groups 1 and 3 (P < .018), but their body mass index was similar. Fasting serum PRL concentrations
were similar among the 3 groups; however, group 2 had higher PRL concentrations throughout the test (P <
.001) and a greater area under the PRL curve than groups 1 and 3 (P < .001), without differences between the
last 2 groups. The differences remained significant after adjustment for age (P < .01). Our results in a small
group of patients with chronic GVHD after allo-HSCT suggest the existence of an increased functional level
of their hypothalamic dopamine tone, which would favor a tendency toward a diminished endogenous pro-
duction, release of pituitary PRL, or both. This could represent an adaptive mechanism aiming to maintain
circulating PRL concentrations within a physiological range.
© 2006 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (allo-HSCT) is a valid treatment for a number of
alignant and nonmalignant bone marrow disorders
1,2]. Graft-versus-host disease (GVHD) complicates
early 50% of allo-HSCTs, and several factors are
nown to be associated and correlated with the devel- [
66pment of GVHD in patients undergoing allo-HSCT
nd might thus be of use to anticipate the develop-
ent of GVHD, thus allowing early modiﬁcation of
mmunosuppressive therapy [3]. GVHD has been ar-
itrarily separated into 2 entities according to its oc-
urrence after the allograft: acute and chronic GVHD
4], with a predominance of a T-helper type 1 (Th1)
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Bytokine pattern in the former and a switch toward a
h2 cytokine proﬁle in the latter [4,5]. Although
uch has been learned about the immunobiology of
VHD, the precise etiopathogenic mechanisms re-
ain largely unknown.
A previous article described increased serum pro-
actin (PRL) concentrations in humans after alloge-
eic bone marrow transplantation for hematologic
alignancy or aplastic anemia complicated by chronic
VHD (beyond day 100 after grafting) [6]. Plasma
RL levels have also been found to be increased in
omen during conditioning and within 30 days after
utologous blood stem cell transplantation for breast
ancer [7]. It is interesting to note that PRL levels
ere higher in women who remained in continuous
omplete remission than in those with only a partial
emission or ensuing early relapse [7].
These ﬁndings are particularly relevant because
RL—whether of pituitary or extrapituitary origin
8]—has long been recognized as a potent Th1 type
ytokine that functions as a comitogen with interleu-
in 2 in the activation and proliferation of T cells and
atural killer cells [9-11], particularly if PRL concen-
rations are within a physiological range [9]. Further-
ore, early animal experiments suggested that PRL
lso participates in the humoral autoimmune response
12,13] and this conﬁrmed in humans with autoim-
une diseases such as systemic lupus erythematosus
14,15]. Thus, there is strong evidence to support its
ey role in the immunomodulation of both the hu-
oral and cellular immune responses in humans
11,16-18]. However, it must be kept in mind that
either too much, or too little PRL may be immuno-
uppressive” [11], particularly if the condition is sus-
ained [9,16]. Despite this knowledge, the information
vailable on PRL and GVHD after allo-HSCT is
canty.
PRL also has been implicated in the restoration of
he hematopoietic homeostasis under conditions of
ysregulation, but not under normal steady-state con-
itions [19]. Furthermore, recombinant human PRL
as been shown to stimulate lymphoid and myeloid
econstitution and/or promote hematopoiesis in dif-
erent preclinical models [19-21].
Under physiological conditions, the pituitary re-
ease of PRL is mainly controlled by a tonic inhibitory
echanism mediated by dopamine (DA) [22]. Both
asal serum PRL concentrations and its response to
he intravenous administration of a DA-blocking
gent, such as metoclopramide, have been considered
good index for evaluating the functional status of the
ypothalamic dopaminergic tone in different clinical
onditions [23-25]. However, the mechanisms con-
rolling the extrapituitary production of PRL, specif-
cally in lymphocytes, are largely unknown [26]. Nev-
rtheless, PRL as an immune cell–derived cytokine
an be “exported” in biologically signiﬁcant amounts i
B & M To the general circulation under special conditions [27]
nd exert its effects at the cellular level as an autocrine,
aracrine, or endocrine factor [9,16]. On the basis of
his information, we aimed to compare the functional
tatus of the hypothalamic dopaminergic tone in pa-
ients with allo-HSCT and chronic GVHD with that
bserved in patients with allo-HSCT without chronic
VHD and in healthy controls.
ATERIALS AND METHODS
The study protocol was approved by the Internal
eview Board and the Human Ethical Committee of
he Centro de Hematología y Medicina Interna de
uebla (Puebla, Mexico), and written informed con-
ent was obtained from all volunteers. The study was
onducted according to the Declaration of Helsinki
as amended October 2000).
tudy Population
The study encompassed 20 volunteers aged 20 to
2 years with a body mass index (BMI) between 20.6
nd 32.9 kg/m2. None drank alcohol regularly or
egularly ingested any medication known to increase
erum PRL concentrations [28] 4 months before the
tudy. All volunteers were clinically euthyroid and had
ormal fasting serum concentrations of thyrotropin
reference values, 0.3-4.2 U/mL), free thyroxine
reference values, 0.8-2.0 ng/dL), and PRL (reference
alues, 20 ng/mL). All individuals were seronegative
or both hepatitis C virus and the human immunode-
ciency virus. The volunteers were classiﬁed into 2
ategories: (1) 10 clinically healthy men (group 1) and
2) 9 consecutive patients with leukemia and 1 patient
ith severe refractory aplastic anemia who underwent
llo-HSCT, 5 of whom (3 men and 2 women) devel-
ped chronic GVHD (group 2) and 5 of whom (3 men
nd 2 women) did not develop GVHD (group 3). Five
atients were allografted for chronic myelogenous
eukemia: 2 for acute myelogenous leukemia, 2 for
cute lymphoblastic leukemia, and 1 for severe refrac-
ory aplastic anemia (Table 1).
atients and Donors
All the patients allografted in the Centro de He-
atología y Medicina Interna de Puebla were pro-
pectively accrued onto the study. Class I and II HLA
ntigens were studied by molecular biology. All pa-
ients with acute leukemia underwent transplantation
n complete remission and had a Karnofsky status of
00% when the procedure was performed. The donor
as an HLA-compatible (5/6 or 6/6) sibling in allnstances.
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5ematopoietic Stem Cell Mobilization
nd Apheresis
Granulocyte colony-stimulating factor (10 g/
g/d) was delivered to the sibling donors on days 5
o 2. The apheresis procedures were performed on
ays 0, 1, and 2, according to the cell counts, by
eans of a Haemonetics V-50 PLUS machine (Hae-
onetics Corporation, Braintree, MA) or a Baxter
-3000 PLUS machine (Baxter Healthcare, Deer-
eld, IL) by using the Spin-Nebraska protocol [29]. A
otal of 5000 to 7000 mL/m2 of blood was processed
n each of the apheresis procedures to obtain a mini-
um of 5  108 mononuclear cells and/or 2 to 6 
06 viable CD34 cells per kilogram of the recipient.
numeration of the total white blood, mononuclear,
nd CD34 cells was performed by ﬂow cytometry
30,31]. No purging procedure was performed.
onditioning and Grafting
The Mexican nonablative stem cell transplanta-
ion conditioning regimen was used [32-35]: it is a
impliﬁcation of the low-intensity conditioning reg-
mens used in Houston [36] and in Jerusalem [37].
ral busulfan 4 mg/kg was delivered on days 6
nd 5; intravenous cyclophosphamide 350 mg/m2,
able 1. Clinical and Relevant Hematologic Data in Healthy
olunteers (Group 1) and in Patients with Leukemia and Bone
arrow Transplantation with (Group 2) and Without Graft-versus-Host
isease (Group 3)
Group Sex
Age
(y)
BMI
(kg/m2)
CD34
(106/kg) Diagnosis
roup 1 (controls)
1 M 48 24.9 — —
2 M 34 22.1 — —
3 M 20 20.6 — —
4 M 23 22.4 — —
5 M 24 25.9 — —
6 M 22 21.7 — —
7 M 27 24.6 — —
8 M 22 25.7 — —
9 M 26 22 — —
10 M 26 27.2 — —
roup 2 (GVHD)
1 M 20 26.7 4.1 CML
2 M 23 31.7 1.9 ALL
3 M 45 31.8 5.9 CML
4 F 30 22.5 9.2 CML
5 F 26 27.2 17.7 CML
roup 3 (GVHD)
1 M 51 27.7 6.9 CML
2 M 50 26.4 0.07* AML
3 M 39 21.1 2.4 AML
4 F 25 20.3 1.2 ALL
5 F 52 32.9 8.4 AA
MI indicates body mass index; CML, chronic myelogenous leu-
kemia; ALL, acute lymphoblastic leukemia; AML, acute my-
elogenous leukemia; AA, aplastic anemia.
Umbilical cord source.n days 4, 3, and 2; and intravenous ﬂudara- k
68ine 30 mg/m2, on days 4, 3, and 2. Oral cyclo-
porin A (CsA) 5 mg/kg was started on day 1, and
ntravenous methotrexate 5 mg/m2 was delivered on
ays 1, 3, 5, and 11. Oral CsA was continued
hrough day 100, with adjustments according to the
evels of whole-blood CsA; it was then tapered over 30
o 60 days. The products of the peripheral blood stem
ell apheresis were reinfused on an outpatient basis on
ays 0 to 2, according to the CD34 cell yield. In one
ase (group 3; case 2), umbilical cord blood cells were
sed instead of peripheral blood stem cells. Acute and
hronic GVHD were deﬁned according to conven-
ional criteria: chronic GVHD was deﬁned as that
ppearing after day 100 [4,38].
himerism Studies
In cases with a sex mismatch, a ﬂuorescent in situ
ybridization technique was performed to demonstrate
he X and Y chromosomes [39,40], whereas restriction
ragment length polymorphism [40,41] studies in the
eripheral blood lymphocytes were used in the other
ases.
xperimental Protocol
All individuals were studied identically. Between
:00 and 8:30 am and after a 10- to 12-hour overnight
ast, an indwelling catheter was placed in a forearm
ein and kept patent with a slow intravenous drip of
.15 mol/L NaCl solution. After a 30-minute rest, 3
asal nonheparinized blood samples were obtained at
5-minute intervals (30, 15, and 0 minutes) and
hereafter at 30, 60, 90, 120, and 180 minutes after a
0-mg intravenous bolus of metoclopramide (Car-
otprim; Laboratorios Carnot, Mexico City, Mexico).
t each sampling time, the ﬁrst 0.3 mL of blood was
iscarded to avoid a dilution error, and all subjects
ere closely monitored for extrapyramidal symptoms.
hysical activity of any kind, smoking, or sleeping was
ot allowed throughout the test. Blood samples were
entrifuged at 3000 rpm, and the serum was kept
rozen at 20°C until duplicate determinations of
RL were performed. In previous studies in a differ-
nt population of patients [42], we found that the early
RL response (0-180 minutes) to metoclopramide
ave the same but qualitatively better information
ompared with the overall response over a period of
hours. The serum PRL concentrations at30,15,
nd 0 minutes in each patient were pooled and ex-
ressed as mean fasting serum PRL concentration.
he area under the PRL curve (AUC-PRL) was cal-
ulated by using a trapezoidal model [43].
ormonal Assays
PRL determinations were performed in duplicate
y using commercially available immunoradiometric
its (Diagnostic Products Corporation, Los Angeles,
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BA), and the intra-assay and interassay coefﬁcients of
ariation for PRL concentrations 30 ng/mL were
% and 8.1%, respectively. For concentrations be-
ween 31 to 300 ng/mL, they were 6.2% and 7.8%,
espectively. PRL kits have been calibrated against the
orld Health Organization 3rd International Refer-
nce Standard Preparation. Serum samples were
ested in 3 assays, and the samples were distributed
qually relative to each group studied. The sensitivity
f the assay was 1.8 ng/mL.
tatistical Analysis
Between-groups differences for age, BMI, mean
asting serum PRL concentrations, and AUC-PRL
ere analyzed by analysis of variance, and ex post facto
ifferences were analyzed with the Tukey test. Serum
RL concentrations during the intravenous metoclo-
ramide were evaluated for both intragroup and in-
ergroup differences by using analysis of variance for
epeated measures. When differences between groups
ere found, a secondary analysis was performed that
djusted for age. The statistical analysis was per-
ormed with SPSS Windows version 11.0 (SPSS Inc.,
hicago, IL). A P value .05 was considered signiﬁ-
ant.
ESULTS
All patients engrafted successfully. Of the patients
ho developed chronic GVHD, only 1 (patient 1) had
ad previous acute GVHD. The chimerism studies
howed that all patients became full chimeras after the
llograft. Four cases of chronic GVHD were limited
orms of the condition, whereas 1 was extensive (pa-
ient 2); all patients had cutaneous forms of GVHD,
nd 1 had liver damage. There were no instances of
eural forms of GVHD. Three patients (cases 1, 2,
nd 3) were given low doses of corticosteroids (pred-
isone 5 mg/d). After achieving remission, patient 2
ad a severe relapse of chronic GVHD with progres-
ive cholestasis; he was treated unsuccessfully with
oth intravenous prednisolone and anti-CD52 mono-
lonal antibody but died 182 days after the allograft
nd 65 days after the metoclopramide test. The rest of
he patients are alive in complete remission.
During the metoclopramide test, none of the vol-
nteers experienced any side effects, including extra-
yramidal symptoms, as the result of an exaggerated
ensitivity to the DA antagonist used. Chronologic
ge was similar in groups 1 and 2 but was signiﬁcantly
ower than in group 3 (P  .018). No differences in
MI were detected among the 3 groups (Table 1).
Fasting PRL serum concentrations were similar
mong the 3 groups, both at each individual basal time
nd as the mean basal concentration (Figure 1). In
esponse to metoclopramide, there was a sharp and a
B & M Tigniﬁcant increase in serum PRL concentrations
ithin 30 minutes (P  .001) and a subsequent steady
ecline until the end of the test in the 3 groups.
owever, the magnitude of the PRL response was
igniﬁcantly greater in group 2 than in groups 1 and 3
hroughout the test (P  .001), without signiﬁcant
ifferences between the last 2 groups. After adjust-
ent for age, the responses in serum PRL concentra-
ions remained signiﬁcantly different when comparing
roup 2 versus groups 1 and 3 (P  .01). There were
o signiﬁcant sex differences in the serum PRL re-
ponse to metoclopramide among the 3 groups (P 
796).
The AUC-PRL was greater in group 2 (mean,
1 914.0 ng/mL/180 min; 95% conﬁdence interval,
0 614.6-13 213.3 ng/mL/180 min) than in group 1
mean, 5932.8 ng/mL/180 min; 95% conﬁdence in-
erval, 4695.8-7169.7 ng/mL/180 min) and group 3
mean, 5676.4 ng/mL/180 min; 95% conﬁdence in-
erval, 5804.6-8923.4 ng/mL/180 min; P  .001). No
igniﬁcant differences were found between groups 1
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5he highest AUC-PRL value in groups 1 and 3 was
elow the lowest individual value in group 2 (Figure 2).
n other words, there was no discernible overlapping
f individual values. There was no correlation be-
ween the AUC-PRL and the number of allogeneic
D34 cells grafted in the patients.
ISCUSSION
In this study we demonstrated, in a small group of
atients who underwent allo-HSCT and later devel-
ped chronic GVHD, a clearly augmented serum
RL response during acute DA blockade with meto-
lopramide compared with the same type of patients
ho did not develop chronic GVHD and compared
ith clinically healthy individuals. There were no sig-
iﬁcant differences among the last 2 types of individ-
als. Consequently, this study offers evidence on the
xistence of an increased functional level of hypotha-
amic DA tone in patients with chronic GVHD after
llo-HSCT, which, acting in concert with hypotha-
amic and/or intrapituitary signals, would favor a ten-
ency toward a diminished pituitary PRL release
nd/or production [22,23,42]. This variance in the
RL responsiveness to metoclopramide could be due
o a hypothalamic or pituitary cause, because it may
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igure 2. Individual values for the area under the prolactin curve
uring the intravenous metoclopramide test in a group of 10 healthy
ontrols, in 5 allografted patients with chronic GVHD, and in 5
llografted patients without GVHD.iffer according to the DA levels in the hypophyseal w
70ortal circulation or to the level of sensitivity of the
actotrophs to DA [22].
The clear difference in PRL response between pa-
ients with chronic GVHD, patients without GVHD,
nd clinically healthy individuals could not be ascribed
o a drug effect because no patient was taking any drug
nown to inﬂuence PRL secretion [28]. The possible
nﬂuence of an excessive BMI (30 kg/m2) in 2 pa-
ients of group 2 also cannot explain the difference
bserved, because obesity is associated with a de-
reased PRL response to metoclopramide [44]. Fur-
hermore, most of the volunteers (18 of 20) had a BMI
etween 20 and 27 kg/m2, considered a normal range
45]. Sex differences seem not to explain the variance
n PRL response either, inasmuch as there were 2
omen in group 2 (GVHD) and also 2 women in
roup 3 (GVHD), and their individual responses lay
ithin those observed for men in the 3 groups (P 
798). Furthermore, the PRL response to metoclopra-
ide is similar during both the follicular and luteal
hases of the menstrual cycle [46].
A drawback of our study is the small number of
atients studied; nevertheless, the differences in the
esults were clear and highly signiﬁcant, and no indi-
idual overlapping was observed in the AUC-PRL
alues between patients with and without GVHD. A
imilar increase in the functional level of the hypotha-
amic DA tone has been recently described in women
ith systemic lupus erythematosus, along with an aug-
ented secretion and release of bioactive lymphocyte-
erived PRL aiming to maintain serum PRL concen-
rations within a physiological range, probably as a
ontribution to downregulate the humoral autoim-
une milieu in these patients [47]. Thus, our ﬁnding
ay also have biological relevance. We hypothesize
hat our patients with chronic GVHD were in a Th2
tatus similar to that found in some autoimmune dis-
ases, in which high serum PRL concentrations con-
ribute to the acceleration of autoantibody production
nd, thus, may become deleterious [48-50]. Indeed,
thers have found increased fasting serum PRL levels
n larger series of patients with chronic GVHD [6],
lthough we did not observe this, most likely because
f the small number of patients studied. Therefore,
he increased functional level of the hypothalamic
one in these patients with chronic GVHD may rep-
esent an adaptive or counterregulatory mechanism
ttempting to maintain the endogenous production
nd/or release of PRL—whether of pituitary or lympho-
yte origin—within a physiological range. Whether or
ot this adaptation inﬂuences the excessive autoimmune
esponse already present in these patients [4,5,38] cannot
e disclosed from this study.
There is a pressing need for new approaches in the
reatment and prevention of the GVHD reaction,
hether acute or chronic, and there is evidence that
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BRL plays an as-yet unrecognized role in the patho-
enesis of GVHD in humans [6,7].
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